APA način citiranja

Pelosof, L., Lemery, S., Casak, S., Jiang, X., Rodriguez, L., Pierre, V., . . . Pazdur, R. (2018). Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib. Oncologist.

Čikaški stil citiranja

Pelosof, Lorraine, et al. "Benefit‐Risk Summary of Regorafenib for the Treatment of Patients With Advanced Hepatocellular Carcinoma That Has Progressed On Sorafenib." Oncologist 2018.

MLA način citiranja

Pelosof, Lorraine, et al. "Benefit‐Risk Summary of Regorafenib for the Treatment of Patients With Advanced Hepatocellular Carcinoma That Has Progressed On Sorafenib." Oncologist 2018.